Investigational drugs for T-cell lymphoma
- 17 December 2015
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 25 (2) , 171-181
Abstract
No abstract availableThis publication has 71 references indexed in Scilit:
- How I treat NK/T-cell lymphomasBlood, 2013
- How I treat adult T-cell leukemia/lymphomaBlood, 2011
- Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma ProjectBlood, 2011
- Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study GroupBlood, 2010
- Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95British Journal of Haematology, 2010
- Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter StudyJournal of Clinical Oncology, 2009
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical OutcomesJournal of Clinical Oncology, 2008
- Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic ScoreJournal of Clinical Oncology, 2006
- Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomasAnnals of Hematology, 2006
- Epidemiology of the non-Hodgkin’s lymphomas: Distributions of the major subtypes differ by geographic locationsAnnals of Oncology, 1998